FTRE · Fortrea Holdings Inc.
$23.63
-1.21% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
20.9
Dividend yield
0.0%
Beta
1.91
Avg volume
2M
Employees
14K
Daily Change %
-1.21%
5 Days Change
6.36%
10 Days Change
14.34%
30 Days Change
22.54%
60 Days Change
30.64%
Month to Day Change
23.30%
Year to Day Change
38.67%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — FTRE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-20
Latest call per bank · past 12 months
UBS
Neutral$24.00
+1.6% vs priceDeutsche Bank
Buy$25.00
+5.8% vs priceBarclays
Overweight$23.00
-2.7% vs priceCitigroup
Buy$22.00
-6.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | UBS | Maintains | Neutral | $22.00 → $24.00 |
| 2026-10-15 | Deutsche Bank | Upgrade | Hold → Buy | $20.00 → $25.00 |
| 2026-10-06 | Barclays | Upgrade | Equal-Weight → Overweight | $22.00 → $23.00 |
| 2026-09-30 | UBS | Initiates | Neutral | $0.00 → $22.00 |
| 2026-08-04 | TD Cowen | Maintains | Buy | $19.00 → $23.00 |
| 2026-07-31 | Citigroup | Maintains | Buy | $20.00 → $22.00 |
| 2026-07-30 | Truist Securities | Maintains | Buy | $19.00 → $26.00 |
| 2026-07-30 | Evercore ISI Group | Maintains | Outperform | $20.00 → $25.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bearish: RSI (14): RSI is 70 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 19.9% above the 50-day MA ($19.70).
- bullish: Price vs 200-day MA: Trading 52.1% above the 200-day MA ($15.54).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.23) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($24.06).
FTRE Price Chart
Loading chart for FTRE…
Fundamentals
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.